Peanut allergy immunotherapy - DMS Imaging
Alternative Names: pnt-ASIT+Latest Information Update: 28 Jun 2022
Price :
$50 *
At a glance
- Originator ASIT biotech
- Developer DMS Imaging; Imperial College of Science, Technology and Medicine; Kings College Hospital
- Class Allergens; Allergy immunotherapies; Antiallergics; Food allergy immunotherapies; Peptides
- Mechanism of Action Immunosuppressants; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Peanut hypersensitivity
Highest Development Phases
- No development reported Peanut hypersensitivity
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Peanut-hypersensitivity in Belgium (Parenteral)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Peanut-hypersensitivity in United Kingdom (Parenteral)
- 05 Nov 2018 Peanut allergy immunotherapy is available for licensing as of 05 Nov 2018. www.asitbiotech.com 809253616